Compare Expeditors International of Wshngtn Inc (EXPD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs TG Therapeutics Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $193.43 (market cap $25.18B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 3.1× TG Therapeutics Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.84% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and TG Therapeutics Inc for 16 Days on average.
| EXPD | TGTX | |
|---|---|---|
Market Cap | $25.18B | $8.16B |
Volume | 1,003,557 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $194.12 | $59.06 |
52-Week Low | $113.13 | $26.94 |
Typical Hold Time | 43 Days | 16 Days |
Enterprise Value | $24.72B | $8.37B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $193.24, up 1.25% with a bullish technical signal. The stock shows strong fundamentals with three consecutive earnings beats and robust profitability metrics including 42.6% ROE. Recent news highlights efficiency initiatives and airfreight demand strength. Moving averages signal bullish momentum while oscillators remain neutral.
Outlook remains positive with earnings momentum and operational efficiency gains, though valuation appears stretched at 28.2 P/E. Risks include competitive pressures and potential freight market volatility. Analyst consensus is cautious with 63.6% hold ratings and $179.43 price target below current levels.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
